Annovis Bio, Inc.
جودة البيانات: 100%
ANVS
NYSE
Manufacturing
Chemicals
KWD 1.59
▼
KWD 0.03
(-1.85%)
القيمة السوقية: 46.29 M
السعر
KWD 1.63
القيمة السوقية
46.29 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Negative free cash flow of -25.62 M
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-183.28%
أقل من متوسط القطاع (-53.47%)
ROIC-146.14%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A
التقييم
PE (TTM)
-1.60
أقل من متوسط القطاع (-1.48)
P/B Ratio3.52
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -1.6 | -1.5 |
| P/B | 3.5 | 1.6 |
| ROE % | -183.3 | -53.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
2 محللين
Strong Buy
الحالي
KWD 1.59
المستهدف
KWD 12.50
KWD 8.00
KWD 12.50
KWD 17.00
التوقعات
مكرر الربحية المستقبلي
-1.47
ربحية السهم المستقبلية
-KWD 1.08
الإيرادات المقدّرة
0.0
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 1.08
-KWD 1.08 – -KWD 1.08
|
0.0 | 1 |
| FY2026 |
-KWD 1.10
-KWD 1.10 – -KWD 1.10
|
0.0 | 1 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.31
-KWD 0.31 – -KWD 0.31
|
0.0 | 1 |
| 2026 Q1 |
-KWD 0.36
-KWD 0.36 – -KWD 0.36
|
0.0 | 1 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.30 | -KWD 0.39 | -30.0% |
| Q32025 | -KWD 0.37 | -KWD 0.37 | 0.0% |
| Q22025 | -KWD 0.39 | -KWD 0.32 | +18.0% |
| Q12025 | -KWD 0.29 | -KWD 0.32 | -10.3% |
ETFs Holding This Stock
BRSIX
BRSIX
0.02% weight
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -28.85 M |
| ROE | -183.28% | ROA | -149.34% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -25.62 M |
| ROIC | -146.14% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | N/A |
| Interest Coverage | N/A | Asset Turnover | 0.00 |
| Working Capital | N/A | Tangible Book Value | 13.16 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.60 | Forward P/E | N/A |
| P/B Ratio | 3.52 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -55.34% | ||
| Market Cap | 46.29 M | Enterprise Value | 31.01 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.40 | Revenue / Share | 0.00 |
| FCF / Share | -0.90 | OCF / Share | -0.90 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 88.79% |
| SBC-Adj. FCF | -27.45 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | -28.85 M | -24.59 M | -56.20 M | -25.33 M | -14.49 M |
| EPS (Diluted) | -1.40 | -2.31 | -6.23 | -3.10 | -1.90 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -29.70 M | -26.69 M | -45.04 M | -25.51 M | -14.54 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 25.22 M | 20.00 M | 38.79 M | 16.52 M | 8.48 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0.0 | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 21.08 M | 13.93 M | 10.21 M | 36.02 M | 46.00 M |
| Total Liabilities | 4.23 M | 4.62 M | 17.96 M | 7.70 M | 1.51 M |
| Shareholders' Equity | 16.85 M | 9.31 M | -7.75 M | 28.32 M | 44.49 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 19.53 M | 10.55 M | 5.75 M | 28.38 M | 45.69 M |
| Current Assets | — | — | 10.21 M | 36.02 M | 46.00 M |
| Current Liabilities | 3.64 M | 3.88 M | 4.28 M | 7.70 M | 1.51 M |
{"event":"ticker_viewed","properties":{"ticker":"ANVS","listing_kind":"stock","pathname":"/stocks/anvs","exchange":"NYSE","country":"US"}}